MUREIDOMYCIN-A, A NEW INHIBITOR OF BACTERIAL PEPTIDOGLYCAN SYNTHESIS
MUREIDOMYCIN-A, A NEW INHIBITOR OF BACTERIAL PEPTIDOGLYCAN SYNTHESIS
复制标题
DOI：
10.1128/aac.35.2.234
复制
发表时间：
1991-02-01
影响因子：
4.9
通讯作者：
INUKAI, M
中科院分区：
文献类型：
--
作者：
ISONO, F;INUKAI, M
MRD是一种具有抗假单胞菌活性的新型肽基核苷类抗生素，在体外合成肽聚糖的系统中，用乙醚处理的铜绿假单胞菌细胞，MRD不仅抑制了UDP-N-乙酰胞壁酰（MurNAc）-五肽和UDP-N-乙酰葡糖胺的肽聚糖合成，而且抑制了脂质中间体的形成。当UDP-MurNAc-五肽与乙醚处理的细胞预孵育时，MRD的两种类型的抑制消失。此外，MRD完全抑制浓度低于MIC的脂质中间体I（十一异戊二烯基-p-p-MurNAc-五肽）的形成。从这些结果可以得出结论，MRD作用的真实的靶标是转位酶，其催化脂质中间体I形成UDP-MurNAc-五肽和脂质载体。
Mureidomycin A (MRD), a novel peptidylnucleoside antibiotic with antipseudomonal activity, inhibited not only peptidoglycan synthesis but also lipid-intermediate formation from UDP-N-acetylmuramyl (MurNAc)-pentapeptide and UDP-N-acetylglucosamine in an in vitro peptidoglycan-synthesizing system, using ether-treated cells of Pseudomonas aeruginosa. Both types of inhibition by MRD disappeared when UDP-MurNAc-pentapeptide was preincubated with ether-treated cells. Moreover, MRD completely inhibited lipid-intermediate I (undecaprenyl-p-p-MurNAc-pentapeptide) formation of a concentration below the MIC. From these results, it was concluded that the real target of MRD's action was translocase, which catalyzes lipid-intermediate I formation form UDP-MurNAc-pentapeptide and a lipid carrier.